The cooperation of Ras -extracellular signal-regulated kinase/mitogen-activated protein kinase and transforming growth factor (TGF)-b signaling provokes an epithelial to mesenchymal transition (EMT) of differentiated p19 ARF null hepatocytes, which is accompanied by a shift in malignancy and gain of metastatic properties. Upon EMT, TGF-b induces the secretion and autocrine regulation of platelet-derived growth factor (PDGF) by upregulation of PDGF-A and both PDGF receptors. Here, we demonstrate by loss-of-function analyses that PDGF provides adhesive and migratory properties in vitro as well as proliferative stimuli during tumor formation. PDGF signaling resulted in the activation of phosphatidylinositol-3 kinase, and furthermore associated with nuclear b-catenin accumulation upon EMT. Hepatocytes expressing constitutively active b-catenin or its negative regulator Axin were employed to study the impact of nuclear b-catenin. Unexpectedly, active b-catenin failed to accelerate proliferation during tumor formation, but in contrast, correlated with growth arrest. Nuclear localization of b-catenin was accompanied by strong expression of the Cdk inhibitor p16
Introduction
Epithelial to mesenchymal transition (EMT) is a fundamental process, which governs morphogenesis during embryonic development and pathological events such as tissue repair and inflammation (Thiery, 2002) . During EMT, epithelial cells switch to a fibroblastoid phenotype, which is accompanied by derangement of apico-basal polarity, loss of cell-to-cell adhesion and the expression of mesenchymal markers. Classes of molecules causally involved in EMT include growth factors such as transforming growth factor (TGF)-b, transcription factors, constituents of intercellular adhesion, components of the cell-to-extracellular matrix (ECM) adhesion axis, cytoskeletal modulators and extracellular proteases. In the last years, EMT has been well recognized to represent an important step in the metastatic process, as carcinoma progression and the acquisition of metastatic abilities are commonly associated with epithelial dedifferentiation and an invasive potential (Friedl and Wolf, 2003) .
Hepatocellular carcinoma (HCC) represents one of the most common cancers worldwide and is characterized by aggressive tumor formation with poor prognosis. The major etiological factors of HCCs such as infection with hepatitis virus and exposure to hepatotoxins result in chronic liver injury and provoke hepatic fibrosis as a wound-healing response, which frequently leads to cirrhosis and subsequent liver failure (Bissell, 2001 ). TGF-b represents an important link between fibrosis and neoplasia in the liver by acting as a pro-fibrogenic factor and as a potent inducer of EMT (Bissell, 2001; Grunert et al., 2003) . Given its antiproliferative and proapoptotic role in the liver, TGF-b is considered to function as a tumor suppressor (Rossmanith and Schulte-Hermann, 2001 ). On the contrary, TGF-b provides tumor-promoting effects in carcinoma cells themselves as well as in the tumor stroma compartment at advanced tumor stages (Rossmanith and SchulteHermann, 2001; Zavadil et al., 2001) . These include TGF-b-induced migration and invasion, suppression of immune surveillance, increased angiogenesis and osteolytic bone metastasis (Derynck et al., 2001; Roberts and Wakefield, 2003; Siegel and Massague, 2003) . Although TGF-b is not detectable in hepatocytes of healthy adult livers, human HCC cells show significant intracellular expression and secretion of TGF-b1, indicating an autocrine regulatory mechanism of TGF-b signaling (Matsuzaki et al., 2000) .
In order to study the molecular mechanisms involved in late stage hepatocarcinogenesis, we established p19 ARF null hepatocytes, which undergo an EMT through the cooperation of Ras -extracellular signal-regulated kinase/mitogen-activated protein kinase (Erk/MAPK) and TGF-b signaling. This EMT model mimics several characteristics of human HCC such as the establishment of an autocrine TGF-b loop, which is responsible for a dramatic shift in malignancy and metastatic behavior in vivo (Mikula et al., 2004; Fischer et al., 2005) . We recently reported that upon hepatocellular EMT, TGFb induces the secretion and autocrine regulation of platelet-derived growth factor (PDGF) by upregulation of PDGF-A ligand and both PDGF receptor subunits (Gotzmann et al., 2006) . PDGF is known as a potent mitogen and chemoattractant for mesenchymal cells and has further been demonstrated to participate in ECM remodulation. Moreover, direct cooperation of PDGF and integrins has been found to enhance cell motility and to prevent apoptosis (Schneller et al., 1997) . Similar to vascular endothelial growth factor, PDGF has been shown to be operative as an angiogenic factor, which promotes vascularization of tumors (Battegay et al., 1994) . In the liver, deregulation of PDGF ligands and receptors has been observed in a variety of diseases such as cirrhosis, regenerative liver growth and human HCC (Pinzani et al., 1996; Xu et al., 2001) . Nevertheless, the functional implications of PDGF activation in parenchymal cells of the liver are still poorly understood.
In the current investigation, validation of PDGF signaling through genetic and pharmacological interference in hepatocellular EMT indicated a crucial role of PDGF in tumor progression and in activation of b-catenin, which accumulates in nuclei of fibroblastoid malignant hepatocytes. This finding is of particular relevance, as about 50% of human HCCs display nuclear localization of b-catenin (de La Coste et al., 1998; Buendia, 2000) . Although b-catenin was expected to be responsible for PDGF-mediated acceleration of tumor growth, we demonstrate that activation of bcatenin confers characteristics of dormant cancer stem cells.
Results
PDGF activates PI3K signaling and b-catenin upon hepatocellular EMT In this study, we employed established MIM hepatocytes either expressing oncogenic Ha-Ras, termed MIM-R or the Ras mutant S35-V12, referred to as MIM-S35 (Table 1, Fischer et al. (2005) ). In contrast to oncogenic Ha-Ras, which provides activation of Erk/MAPK as well as phosphatidylinositol-3 kinase (PI3K) in MIM-R hepatocytes, S35-V12-Ras selectively activates the Erk/ MAPK pathway in response to cognate receptor stimulation. As recently demonstrated, both MIM-R and MIM-S35 hepatocytes undergo EMT in cooperation with TGF-b (Fischer et al., 2005) . Furthermore, both respective fibroblastoid cell lines derived from MIM-R and MIM-S35 hepatocytes, termed MIM-RT and MIM-ST (Table 1) , show activated Erk/MAPK and PI3K signaling resulting from long-term treatment with TGF-b. As hepatocellular EMT has been found to associate with a TGF-b-induced autocrine PDGF secretion (Gotzmann et al., 2006) , we addressed the question whether PDGF is responsible for the activation of PI3K. Therefore, we employed MIM-R and MIM-S35 hepatocytes expressing the dominant-negative (dn)PDGF-receptora, termed MIM-R-dnP and MIM-S35-dnP, respectively, and their fibroblastoid derivatives (MIM-RT-dnP and MIM-ST-dnP), which resulted from TGF-b treatment (Table 1) . Western blot analyses revealed that MIM-RT-dnP cells showed unchanged phospho-protein kinase B (Akt) levels when compared with MIM-RT cells, as these cells harbor oncogenic Ha-Ras providing PDGF-independent PI3K signaling ( Figure 1a and b) . In contrast, MIM-ST-dnP showed reduced phospho-Akt levels, indicating that PDGF activates PI3K in MIM-ST cells (Figure 1c ). These data 
Abbreviations used for cell lines: MIM, parental p19 ARF null hepatocytes; R, express oncogenic Ha-Ras; S, express S35-V12 Ras; T, cells treated with TGF-b for more than 14 days in culture; dnP, dn PDGF receptor a; ca b-catenin, express constitutive active truncated b-catenin.
a The arabic numeral in the bracket refers to subclone 2. could be confirmed by Western blot analyses of MIM-ST cells after pharmacological intervention with PDGF receptor signaling. Treatment of MIM-ST cells with STI571, a low molecular weight inhibitor demonstrated to specifically interfere with the tyrosine kinase activity of PDGF receptors (Capdeville et al., 2002) , resulted in low phospho-Akt levels comparable to the one observed in MIM-ST-dnP cells ( Figure 1c) .
As Akt has been reported to promote stabilization and nuclear accumulation of b-catenin, we analysed the PDGF-dependent transcriptional activity of b-catenin in EMT. As determined by reporter gene assays, MIM-RT cells exhibited high b-catenin activity similar to MIM-RT-bcat hepatocytes expressing a non-destructible and thus constitutive active mutant of b-catenin (Barth et al., 1999; Reya et al., 2003) (Table 1 , Figure 1d ). In contrast, MIM-RT-dnP cells showed reduced b-catenin activity comparable to MIM-RT-Axin hepatocytes expressing a negative regulator of b-catenin (Zeng et al., 1997; Jho et al., 2002) . Unexpectedly, MIM-ST cells displayed low b-catenin activity, which remained unchanged upon genetic interference with PDGF. Taken together, these data suggest that PDGF is able to activate signaling effectors such as PI3K-Akt, as shown in MIM-ST cells. In addition, PDGF is capable to provide activation of b-catenin upon hepatocellular EMT, independent of PI3K-Akt, as detected in MIM-RT cells.
PDGF is involved in proliferation, cell-substratum interaction and migration In order to reveal the mechanisms by which PDGF leads to increased tumor growth, as published recently (Gotzmann et al., 2006) , we performed a panel of in vitro assays. Proliferation kinetics showed unchanged growth behavior of malignant epithelial hepatocytes irrespective of genetic interference with PDGF signaling (Figure 2a) . In contrast, hepatocytes expressing dnPDGF-Ra displayed growth retardation after treatment with TGF-b, whereby MIM-S35-dnP cells were more sensitive towards TGF-b-mediated growth suppression than MIM-R-dnP (Figure 2b ), suggesting a protecting role of PI3K signaling. Interestingly, the extend of TGF-b-induced growth retardation in vitro was found to depend on the attachment to the substratum, as cells cultured on plastic showed a more pronounced decrease in proliferation than those growing on rat tail collagen-coated culture dishes (Figure 2b and c). In particular, MIM-ST-dnP cells failed to attach and to spread on uncoated tissue culture plastic (Figure 3 ), although they exhibited attachment similar to MIM-RT cells on collagen-coated plates (data not shown). Results from semiquantitative reverse transcriptase-polymerase chain reaction analysis suggested that PDGF enhances the capability of TGF-b-treated fibroblastoid hepatocytes to grow on plastic through altered synthesis of ECM components such as increased expression of pro-collagen I and laminin 5a, and changes in integrin expression patterns (data not shown). These PDGF-dependent signals for changes in cell-substratum interaction might be mediated by the PI3K-Akt pathway, as MIM-RT-dnP harboring active Akt showed unperturbed adhesion to plastic (Figure 3 ). To study the influence of PDGF on cell motility, we determined the migration of fibroblastoid hepatocytes through Transwell filters (Figure 3 ). Fixation and visualization of migrating hepatocytes were performed 20 h after seeding on membranes in order to minimize the influence of cell proliferation. Both, MIM-RT-dnP and MIM-ST-dnP cells displayed a strongly reduced migratory potential. Noteworthy, all corresponding epithelial cell lines without TGF-b treatment equally failed to migrate through Transwells (data not shown). These data provide evidence that PDGF is crucially involved in TGF-b-mediated cell migration of hepatocytes upon EMT.
Inhibitor studies using various concentrations of STI571 indicated that PDGF protects cells from apoptosis upon hepatocellular EMT, as fibroblastoid MIM-RT cells were more sensitive to STI571-induced cell death than epithelial MIM-R, as shown by caspase 3 activation after STI571 administration ( Figure 2d ). Comparable results were obtained from the analysis of cell viability by determination of lactate dehydrogenase release (data not shown). These data suggest that the increased sensitivity of hepatocytes that have undergone EMT to STI571 depends on PDGF receptor expression (Gotzmann et al., 2006) . 
PDGF accelerates tumor formation
In order to rule out negative selection of cells carrying dnPDGF-Ra, we performed single-cell cloning and employed the resulting cell lines, termed MIM-R-dnP2 and MIM-S35-dnP2, and their fibroblastoid derivative cell lines for tumor formation in vivo by subcutaneous injection into severe combined immunodeficiency (SCID) mice (Table 1, Figure 4a ). As expected for control cells, tumors generated from MIM-RT cells were larger than those from MIM-R, whereby both MIM-S35 and MIM-ST-derived tumors even exceeded those obtained from MIM-RT cells (Fischer et al., 2005). Analyses of tumor weights showed a strong reduction of tumors derived from cells expressing the dnPDGF-Ra. Interestingly, this could be observed for both types of tumors either generated from fibroblastoid MIM-RT-dnP2 or epithelial MIM-R-dnP2 hepatocytes ( Figure 4a ). As epithelial hepatocytes do not express detectable levels of PDGF receptors in vitro (Gotzmann et al., 2006) , these data point to a putative induction of TGF-b signaling along with subsequent expression of PDGF receptors in vivo, which might be caused by the tumor microenvironment. Surprisingly, interference with PDGF signaling in MIM-ST hepatocytes caused a lower reduction of tumor size than in MIM-RT, although in vitro, MIM-ST-dnP showed the most severe defects in adhesion, migration and proliferation.
Immunohistochemical staining of tumor sections for proliferating cell nuclear antigen (PCNA), a marker for proliferation, correlated with tumor weights generated from corresponding cell lines, that is, both MIM-RTand MIM-ST-derived tumors showed a large proportion of cells in S phase as compared to tumors generated from MIM-R-, MIM-S35-and dnPDGF-Ra-expressing cells (Figure 4b Functional validation of active b-catenin in hepatocellular EMT Nuclear localization of b-catenin and thus transcription of Wnt target genes is considered as a hallmark of EMT and is observed in about 50% of human HCCs (de La Coste et al., 1998; Buendia, 2000) . As the impact of b-catenin activation in hepatocellular tumorigenesis is controversially discussed, we aimed at studying the role of b-catenin by employing MIM-R hepatocytes either activating or repressing this signaling pathway by the expression of constitutive active b-catenin or Axin, respectively (Zeng et al., 1997; Barth et al., 1999; Jho et al., 2002; Reya et al., 2003) . In order to prevent negative selection due to possible growth suppressing functions, single-cell cloning was performed resulting in cell lines termed MIM-R-bcat and MIM-R-Axin and their TGF-b-treated derivatives MIM-RT-bcat and MIM-RT-Axin (Table 1) . Noteworthy, several singlecell clones were established, which showed comparable characteristics, however, one clone was chosen for further studies.
Tumor formation after subcutaneous injection of cells into SCID mice revealed a strong reduction of tumor growth upon constitutive activation of b-catenin (Figure 5a ). The tumor suppressing role of active b-catenin was confirmed by the enhanced tumor size derived from hepatocytes expressing Axin (Figure 5b ). In addition, immunohistochemical analyses of experimental tumors revealed a strong correlation of PCNA staining and the observed tumor volumes (Figure 5c ). The functionality of the employed hepatocytes activating or repressing the Wnt pathway was confirmed by immunohistochemistry using an antibody against the C-terminus of b-catenin (Figure 6a ), as the antibody recognizing active b-catenin stained only the endogenous protein but failed to detect the constitutive active b-catenin mutant (data not shown). As b-catenin is known to positively regulate the expression of proliferation-associated target genes such as c-myc and cyclin D1, we employed the respective tumor sections for immuno- . Accordingly, sections of MIM-RT-bcat derived tumors strongly stained for p16 INK4A (Figure 6a ), hence, explaining the observed cell cycle arrest during tumor formation in vivo. Taken together, these data demonstrate that b-catenin might even counteract PDGF-induced proliferation in hepatocellular EMT.
An important aspect in the metastatic spreading of cancer cells is the ability to survive in the blood or lymph stream, in contrast to non-metastatic adhering cells, which undergo apoptosis shortly after loss of cellsubstratum interaction (Chambers et al., 2002) . In order to investigate detachment-induced apoptosis, known as anoikis (Frisch and Screaton, 2001 ), we analysed caspase 3 activity after seeding of cells either on plastic substratum or on agarose-coated culture dishes, the latter suitable to prevent attachment and to monitor induction of anoikis. MIM-RT and MIM-RT-bcat hepatocytes displayed only a moderate increase of caspase 3 activity on agarose compared to standard culture conditions (Figure 6b ). In contrast, caspase 3 activity was strongly induced in MIM-RT cells expressing the dnPDGF-Ra, and to a lower extent in those expressing Axin, when seeded on agarose. Taken together, the sensitivity to anoikis negatively correlates with b-catenin activation, indicating that active b-catenin protects malignant hepatocytes from anoikis, which might be a pre-requisite for metastatic dissemination.
Discussion
The hepatocellular EMT driven by the cooperation of Ras -Erk/MAPK and TGF-b signaling mimics several important features of human HCC progression, and is thus being considered as a significant correlate to the liver cancer situation. In the majority of human HCCs, the Erk/MAPK pathway has been described to be activated (Nijhara et al., 2001; Tsuboi et al., 2004) . Once activated, TGF-b is supposed to switch to a tumorprogressive function in (pre)-cancerous hepatocytes. The TGF-b stimulus itself arises from activated hepatic stellate cells and myofibroblasts, which are the major producers of this cytokine during fibrosis and cirrhosis, both predisposing for the development of HCC Mikula et al., 2006) . During hepatocellular EMT in vitro as well as upon progression of the majority of human HCCs, hepatocytes establish an autocrine regulation of TGF-b signaling, which leads to a metastatic phenotype and aggressive tumor progression (Gotzmann et al., 2002; Fischer et al., 2005) . In this study, we demonstrate that TGF-b-induced PDGF is operative in promoting proliferation, cell-substratum interaction and migration by activating PI3K and b-catenin. Although positively regulated by PDGF, b-catenin acts antiproliferative in malignant hepatocytes and provides resistance against anoikis.
Our finding of b-catenin activation by PDGF is supported by a recent report of Zhou et al. (2003) , demonstrating that STI571 effectively inhibited b-catenin signaling in a dose-dependent manner. This raised the question how b-catenin activation is induced upon EMT. An essential mechanism facilitating b-catenin signaling during EMT might be the downregulation of E-cadherin by TGF-b-mediated induction of snail and delta-EF-1 along with disassembly of intercellular adherence junctions (Gotzmann et al., 2006) , thereby releasing b-catenin from cell boundaries (Lu et al., 2003) . In addition, overexpression of upstream components of Wnt signaling such as the Wnt receptor frizzled might cause b-catenin activation (Merle et al., 2004) , which is supported by data obtained from expression profiling of hepatocellular EMT showing a sevenfold increase of frizzled-1 (data not shown). One further mechanism involving PDGF is the activation of the PI3K-Akt pathway resulting in the inhibition of glycogen synthase kinase 3b (GSK-3b) and allowing b-catenin to translocate to the nucleus in order to activate T-cell factor/lymphoid enhancing factor-dependent transcription (Desbois-Mouthon et al., 2001). However, the interference with PDGF signaling in MIM-RT-dnP cells showing disruption of b-catenin transactivation and nuclear localization even in the presence of high phospho-Akt levels does not support this hypothesis (Figures 1d and 4b) . Thus, there must be another regulatory link between PDGF and b-catenin. Interestingly, activation of peroxisome proliferator-activated receptor-g (PPAR-g) has been shown to suppress b-catenin levels and to antagonize b-catenin-dependent reporter gene activity (Lu et al., 2005) . In line with these data, expression profiling of hepatocellular EMT revealed a strong (greater than fivefold) downregulation of PPAR-g in MIM-RT cells (data not shown). This is of particular relevance, as PDGF was reported to decrease ligand-activated PPAR-g transcriptional activity (Galli et al., 2000) as well as PPAR-g protein expression (Artemenko et al., 2005) . It remains to be elucidated whether this mechanism plays a role in b-catenin regulation during hepatocellular EMT.
Functional validation of active b-catenin revealed suppression of proliferation in vitro and of tumor growth in vivo upon EMT (data not shown and Figure 5a ). This was surprising, as b-catenin activation in malignancies is often reported to be associated with enhanced proliferation (Nhieu et al., 1999; Saldanha et al., 2004 ) and well-known target genes of b-catenin such as c-myc and cyclin D1 encode important positive regulators of cell proliferation (He et al., 1998; Shtutman et al., 1999) . Nevertheless, evidence has accumulated that b-catenin exerts also a growth arresting function (Damalas et al., 2001) . Tumor sections of malignant hepatocytes constitutively activating b-catenin strongly stained for the cell cycle inhibitor p16
INK4A
, which is suggested to be responsible for the observed growth arrest (Figure 6a ). Comparable to our findings, Jung et al. (2001) observed nuclear b-catenin accumulation and concomitant expression of cyclin D1 and p16
INK4A at the invasive fronts of colorectal adenocarcinomas, which represent regions of low proliferation, and hence discussed p16
INK4A as potential new target gene for b-catenin. Apparently, b-catenin executes a dual role with respect to proliferation, which might explain the controversial discussions about the relationship between b-catenin activation and clinical outcome in human HCC. Most remarkably, some studies demonstrated a significant correlation between nuclear b-catenin, high grade of differentiation and better prognosis (Mao et al., 2001) , whereas others reported an association with poor survival and invasive tumors (Wong et al., 2001) .
Furthermore, we found that active b-catenin protects malignant hepatocytes from anoikis (Figures 1d, 6b) , thereby conferring the capability to survive in suspension, which represents a crucial pre-requisite for the survival of spreading cells after intravasation into the vasculature. Recent reports underline the fatal role of b-catenin in cancer progression by rescuing cells from anoikis (Weng et al., 2002) . On the other hand, the acquisition of migratory potential appears to be independent of b-catenin activation, as investigations of fibroblastoid cell lines by Transwell assays revealed no significant difference in migration between MIM-RT and MIM-RT-bcat (data not shown). Moreover, MIM-ST cells harboring low b-catenin activity efficiently migrated through Transwell filters like MIM-RT cells (Figure 3) . Thus, migration appears to depend exclusively on TGF-b and PDGF signaling.
Taken together, constitutive activation of b-catenin in hepatocytes that have undergone TGF-b-mediated EMT conferred characteristics of cell cycle arrested and anoikis-resistant cancer cells. These features point to the presence of a dormant cancer stem cell phenotype, which is stabilized by b-catenin and is involved in proximal and distal colonization. These results strongly fit into the migratory cancer stem cell concept, as reported recently (Brabletz et al., 2005) . Accordingly, invasive cancer stem cells might result from preceded EMT and acquired stemness, both regulated by fundamental embryonic pathways such as TGF-b and the Wnt pathway.
The quiescence of a subpopulation of tumor cells might render them more resistant to standard chemotherapy that targets proliferating cells and could therefore be responsible for postoperative disease recurrence, as often observed in HCC. These data implicate important consequences for therapeutic intervention of aggressive HCCs, suggesting TGF-b and PDGF as promising targets for anticancer drug development. Moreover, nuclear b-catenin accumulation may become valuable as diagnostic target for slowly growing tumors with high metastatic potential and a certain resistance to cytostatic chemotherapy. In this case, a combined therapy of cytostatic drugs and STI571 or other receptor tyrosine kinase inhibitors for PDGF should be taken into consideration.
Materials and methods
Cell culture MIM-R and MIM-S35 hepatocytes were generated by stable retroviral transmission of immortalized p19 ARF null hepatocytes (MIM) either with a construct bicistronically expressing oncogenic v-Ha-Ras and green fluorescent protein or with the Ras mutant S35-V12-Ras, respectively, as outlined recently (Fischer et al., 2005) . For genetic interference with PDGF signaling, MIM-R and MIM-S35 cells were retrovirally transmitted with a vector bicistronically expressing the dnPDGF-receptora and red fluorescent protein (Yu et al., 2000; Gotzmann et al., 2006) , resulting in MIM-R-dnP and MIM-S35-dnP cell lines, respectively. In order to study the role of b-catenin in hepatocellular EMT, we used MIM-R hepatocytes expressing either the constitutive active mutant b-cateninDGSK-KT3 (MIM-R-bcat) or its negative regulator Axin (MIM-R-Axin) after retroviral transmission (Zeng et al., 1997; Barth et al., 1999; Reya et al., 2003) . All cells were grown in RPMI 1640 plus 10% fetal calf serum and antibiotics at 371C and 5% CO 2 , and were routinely screened for the absence of mycoplasma. In kinetic studies, recombinant human TGF-b1 (R&D Systems, Minneapolis, MN, USA) was used at a concentration of 2.5 ng/ml for the first 72 h of administration. For long-term treatment of cells, TGF-b1 was added at a concentration of 1 ng/ml. Treatment of epithelial cells, such as MIM-R and MIM-S35, with TGF-b1 over 14 days resulted in stable fibroblastoid cell lines, termed MIM-RT and MIM-ST, respectively. Fibroblastoid cells were grown on plastic, whereas epithelial cells required culture dishes coated with rat tail collagen, prepared as described (Gotzmann et al., 2006) . Recombinant human PDGF-A/B (R&D Systems) was used at a concentration of 1 ng/ml. The pharmacological inhibitor STI571 (also known as imatinib mesylate/Gleevec; a kind gift of Novartis International AG, Basel, Switzerland) was used at a concentration of 2.5 mM unless otherwise indicated in the text.
Western blot analysis
The preparation of cellular extracts, separation of proteins by sodium dodecylsulfate-polyacrylamide gel electrophoresis and immunoblotting were carried out as described recently (Gotzmann et al., 2002) . The protein extract from 1 Â 10 5 cells per sample was loaded onto gels, and immunological detection of proteins was performed with the SuperSignal detection system (Pierce Chemical Company, Rockford, IL, USA). The following primary antibodies were used: anti-phospho-Akt (Cell Signaling, Beverly, MA, USA), 1:1000; anti-Akt (Transduction Laboratories, Lexington, UK). Secondary antibodies (Calbiochem, LaJolla, CA, USA) were used at dilutions of 1:10 000.
Transient transfections and reporter gene assays
Cells were plated at a density of 5 Â 10 4 cells per 12-well plate 1 day before transient transfection with Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA), which was used as recommended by the manufacturer. b-Catenin-dependent transactivation was determined by comparing results obtained from the reporter constructs Topflash and Fopflash (Friedl et al., 2000) . All luciferase reporters were co-transfected with a b-galactosidase reporter (Friedl et al., 2000) in a ratio of 4:1. After cell lysis, the luciferase activity was determined using a Luminoskan (Labsystems, Farnborough, UK). All assays were performed in triplicate and results represent the averages of three independent experiments after normalization to b-galactosidase activities.
Proliferation kinetics
Cells (2 Â 10 5 ) were seeded in duplicate on Petri dishes with the indicated culture conditions. The number of cells in the corresponding cell populations was determined periodically in a multichannel cell analyzer (CASY; Scha¨rfe Systems, Reutlingen, Germany). Cumulative cell numbers were generated from the absolute cell counts and their calculated dilution factors (Gotzmann et al., 2002) . Proliferation kinetics have been performed in triplicate of which one representative is shown.
Analysis of caspase 3 activity
Cells were scraped on ice in phosphate-buffered saline (PBS) and lysed in 5 mM Tris/HCl pH 8.0, 20 mM ethylenediaminetetraacetic acid, 0.5% Triton X-100 at 41C. After centrifugation at 13 000 g for 10 min, protein concentration of cell lysates was determined by using the Bio Rad protein assay kit (Bio Rad Laboratories, Richmond, CA, USA). Thirty micrograms protein per condition was mixed with 20 mmol/l N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid pH 7.0, 10% glycerol, 2 mmol/l dithiotreitol and 20 mol/l Ac-DEVD-AMC substrate (Becton-Dickinson, Franklin Lakes, NJ, USA). After 2 h of incubation at 371C in the dark, enzymatic activity was measured in a Microplate Fluorescence Reader FL600 (Bio-Tek, Winooski, VT, USA). A unit of caspase activity is defined as the amount of active enzyme necessary to produce an increase in one arbitrary unit in the luminescence spectrophotometer after 2 h. Results are presented as units of caspase activity per microgram protein, as described previously .
Transwell assay Cells (4 Â 10 4 ) were seeded on 8 mm pore size Transwell filters for 24-well plates (Corning Costar, Cambridge). After 20 h, cells on the inner side of the Transwell cups were removed with cotton swabs and the membranes with the migrated cells were washed in PBS and fixed in methanol for 2 min. After washing, the nuclei of migrated cells were stained with Hoechst 33258 (Sigma, St Louis, MO, USA) diluted 1:10 000 with PBS for 10 min in the dark. After washing, membranes were embedded with mowiol. Pictures were taken under ultraviolet (UV)-light using a fourfold magnification. Assays for each condition were performed in triplicate and representative pictures are shown.
Tumor formation in vivo Cells of the respective cell type were detached from the tissue culture plate, washed with PBS, and resuspended in Ringer solution. Subsequently, 1 Â 10 6 cells in 100 ml Ringer solution were subcutaneously injected into immunodeficient SCID/ BALB/c recipient mice. Tumor formation was periodically measured by palpation, and the tumor size was determined using a vernier caliper. Tumor volume was calculated from tumor size using the formula diameter Â diameter Â length/2, and the tumor weight in milligram was determined as described recently (Gotzmann et al., 2002) . Tumor incidences were equal to 100%, which means that all injected cell populations gave rise to experimental tumors. All experiments were performed in triplicate and carried out according to the Austrian guidelines for animal care and protection.
Immunohistochemistry of experimental tumors SCID mice were sacrificed and the obtained tumors were fixed in 4% phosphate-buffered formaldehyde overnight at 41C (Mikula et al., 2004) . For immunohistochemical analyses, paraffin-embedded sections (4 mM) were treated with citric acid buffer (0,01 M, pH 6.0) before staining with the following antibodies: anti-PCNA (Dako, Carpinteria, CA, USA), 1:100; anti-active b-catenin, clone 8E7 (Upstate Biotechnology, Lake Placid, NY, USA), 1:100; anti-b-catenin (Transduction laboratories, Lexington, UK), 1:100; anti-c-myc (Santa Cruz Biotechnology, CA, USA), 1:200; anti cyclin D1 (Neomarkers, Fremont, USA), 1:200; anti-p16 INK4A (Santa Cruz Biotechnology), 1:200.
